From the UK to the USA - Melanoma Matters is on a mission!
Hosts James Larkin and Sapna Patel are spreading the word on melanoma, one podcast at a time. Tune in for a critical review of the literature and a discussion of how we incorporate the data into our practices...across the pond(s).
#MelanomaMatters video podcast
Ep 88: Negative Adjuvant Doublet Studies (CM915, KV010, RELA098)
Melanoma Matters: Why Adjuvant Doublet Immunotherapy Fell Short
Hobbies - James wishes he was surfing more
This episode breaks down three negative adjuvant melanoma trials testing combination immunotherapy against anti PD 1 monotherapy. The discussion focuses on why toxicity rises without clear efficacy gains, and what these results mean for adjuvant and neoadjuvant strategy going forward.
James Larkin and Sapna Patel also dig into a bigger question: if combination therapy helps in metastatic disease, why does it seem to lose its edge in microscopic or adjuvant disease?
Key topics
In this episode, the hosts review three adjuvant trials:
CheckMate 915
Relativity 098
KeyVibe 010
The bottom line across all three studies is negative efficacy for combination therapy versus monotherapy in the adjuvant setting.
The conversation emphasizes toxicity and discontinuation as a major issue with combination arms, especially when patients stop early because of adverse effects rather than progression.
They revisit the CheckMate 915 dosing question, noting that the ipilimumab exposure in that study was much lower than the classic EORTC adjuvant regimen.
The hosts compare dosing intensity and cumulative dose across adjuvant and metastatic settings, including the idea that dose density may matter as much as total dose.
The episode raises a larger strategic question for melanoma care:
Should adjuvant therapy remain monotherapy?
Should neoadjuvant treatment replace some adjuvant use?
Should patients receive both?
25 Aug 2026
Ep 86: Teaser Tudriqev (RP1) FDA Approval
James asks the big question
25 Aug 2026
Ep 87: INTerpath-001 Press Release - August 2026
In this episode, Sapna and James discuss the INTerpath-001 press release describing primary endpoint (RFS) and key secondary endpoint (DMFS) findings from the randomized phase 3 study of individualized neoantigen therapy plus pembrolizumab for resected stage IIB to IV melanoma. No data were shared, only descriptive findings of "statistically signficant" and "clinically meaningful" results. As James puts it, one of these is binary, the other is subjective.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
4.0 / 5
4 ratings
Spotify
5.0 / 5
14 ratings
Podcast Authority Score: 48 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
